Induced differentiation, the cell cycle, and the treatment of cancer

Pharmacology and Therapeutics

Volumn 69, Issue 2, 1996, Pages 97-102

  Rifkind, Richard A ^a   Richon, Victoria M ^a   Marks, Paul A ^a  

^a Weill Cornell Graduate School of Biomedical Sciences   (United States)

Author keywords

cancer; cell cycle; chemotherapy; differentiation; erythroleukemia; hexamethylene bisacetamide

Indexed keywords

HEXAMETHYLENEBISACETAMIDE;

ANIMAL CELL; CANCER THERAPY; CELL CYCLE; CELL DIFFERENTIATION; CELL DIVISION; DNA SYNTHESIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; RETINOBLASTOMA; REVIEW;

EID: 0029927535     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(95)02044-6     Document Type: Review

References (59)

1. Andreeff, M., Stone, R., Michaeli, J., Young, C. W., Tong, W., Sogoloff, H., Ervin, T., Kufe, D., Rifkind, R. A. and Marks, P. A. (1992) Hexamethylene bisacetamide in myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML): a phase II clinical trial with a differentiation inducing agent. Blood 80: 2604-2609.
2. Arcangeli, A., Carla, M., Del Bene, M. R, Becchetti, A., Wanke, E. and Olivotto, M. (1993) Polar/apolar compounds induce leukemia cell differentiation by modulating cell-surface potential. Proc. Natl. Acad. Sci. USA 90: 5858-5862.
3. Breslow, R., Jursic, B., Yan, Z. F., Friedman, E., Leng, L., Ngo, L., Marks, P. A. and Rifkind, R. A. (1991) Potent cytodifferentiating agents related to hexamethylene bisacetamide. Proc. Natl. Acad. Sci. USA 88: 5542-5546.
4. 1 phase of the cell cycle. Proc. Natl. Acad. Sci. USA 92: 2869-2873.
5. Clarke, M. F., Kukowska-Latto, J. R., Westin, E., Smith, M. and Prochownik, E. V. (1988) Constitutive expression of a c-myb cDNA blocks Friend murine erythroleukemia cell differentiation. Mol. Cell. Biol. 8: 884-892.
6. 1-S phase protein kinase. Science 257: 1958-1961.
7. Dynlacht, B. D., Flores, O., Lees, J. A. and Harlow, E. (1994) Differential regulation of E2F trans-activation by cyclin/cdk2 complexes. Genes & Dev. 8: 1772-1786.
8. Egorin, M. J., Sigman, L. M., VanEcho, D. A., Forrest, A., Whitacre, M. Y. and Aisner, J. (1987) Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion. Cancer Res. 47: 617-623.
9. El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W. and Vogelstein, B. (1995) WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
10. Ewen, M. E., Sluss, H. K., Whitehouse, L. L. and Livingston, D. M. (1993) TGF-β inhibition of cdk4 synthesis is linked to cell cycle arrest. Cell 74: 1009-1020.
11. Fibach, E., Reuben, R. C., Rifkind, R. A. and Marks, P. A. (1977) Effect of hexamethylene bisacetamide on the commitment to differentiation of murine erythroleukemia cells. Cancer Res. 37: 440-444.
12. Friend, C., Scher, W., Holland, J. and Sato, R. (1971) Hemoglobin synthesis in murine virus-induced leukemia cells in vitro: stimulation of erythroid differentiation. Proc. Natl. Acad. Sci. USA 68: 378-382.
13. Gambari, R., Terada, M., Bank, A., Rifkind, R. A. and Marks, P. A. (1978) Synthesis of globin mRNA in relation to the cell cycle during induced murine erythroleukemia differentiation. Proc. Natl. Acad. Sci. USA 75: 3801-3804.
14. 1/early S. Proc. Natl. Acad. Sci. USA 76: 4511-4515.
15. INK4B is a potential effector of TGF-β induced cell arrest. Nature (London) 371: 257-261.
16. 1 cyclin dependent kinase. Cell 75: 805-816.
17. Kiess, M., Gill, R. M. and Hamel, P. A. (1995) Expression of the positive regulator of cell cycle progression, cyclin D3, is induced during differentiation of myoblasts into quiescent myotubes. Oncogene 10: 159-166.
18. Kiyokawa, H., Richon, V. M., Rifkind, R. A. and Marks, P. A. (1994) Suppression of cyclin-dependent kinase 4 during induced differentiation of erythroleukemia cells. Mol. Cell. Biol. 14: 7195-7203.
19. 1 phase of the cell cycle. Science 257: 1689-1694.
20. 1 progression in mammalian cells: inhibition of cyclin E-dependent kinase by TGFβ. Science 260: 536-539.
21. Krek, W., Livingston, D. M. and Shirodkar, S. (1993) Binding to DNA and the retinoblastoma gene product promoted by complex formation of different E2F family members. Science 262: 1557-1560.
22. Laiho, M., DeCaprio, J. A., Ludlow, J. W., Livingston, D. M. and Massague, J. (1990) Growth inhibition by TGF-β linked to suppression of retino-blastoma protein phosphorylation. Cell 62: 175-185.
23. La Thangue, N. B. (1994) DP and E2F proteins: components of a heterodimeric transcription factor implicated in cell cycle control. Curr. Opin. Cell Biol. 6: 443-450.
24. Leng, L., Yu, F., Dong, L., Busquets, X., Osada, S.-i., Richon, V. M., Marks, P. A. and Rifkind, R. A. (1993) Differential modulation of PKC isoforms in erythroleukemia during induced differentiation. Cancer Res. 53: 5554-5558.
25. Levy, J., Terada, M., Rifkind, R. A. and Marks, P. A. (1975) Induction of erythroid differentiation by dimethylsulfoxide in cells infected with Friend virus: relationship to cell cycle. Proc. Natl. Acad. Sci. USA 72: 28-32.
26. Marks, P. A. and Rifkind, R. A. (1978) Erythroleukemic differentiation. Annu. Rev. Biochem. 47: 419-448.
27. Marks, P. A. and Rifkind, R. A. (1984) Differentiation modifiers. Cancer 54: 2766-2769.
28. Marks, P. A., Richon, V. M., Kiyokawa, H. and Rifkind, R. A. (1994) Inducing differentiation of transformed cells with hybrid polar compounds. Proc. Natl. Acad. Sci. USA 91: 10251-10254.
29. 1 phase of the cell cycle. Cell 65: 701-713.
30. McClinton, D., Strafford, J., Brents, L., Bender, T. S. and Kuehl, W. M. (1990) Differentiation of mouse erythroleukemia cells is blocked by late up-regulation of a c-myb transgene. Mol. Cell. Biol. 10: 705-710
31. Melloni, E., Pontremoli, S., Michetti, M., Sacco, O., Cakiroglu, A. G., Jackson, J. F., Rifkind, R. A. and Marks, P. A. (1987) Protein kinase C activity and hexamethylene bisacetamide induced erythroleukemia cell differentiation. Proc. Natl. Acad. Sci. USA 84: 5282-5286.
32. Michaeli, J., Busquets, X., Orlow, I., Younes, A., Colomer, D., Marks, P. A., Rifkind, R. A. and Kolesnick, R. N. (1992a) A rise and fall in 1,2 diacylglycerol content signals hexamethylene bisacetamide-induced erythropoiesis J. Biol. Chem. 267: 23463-23466.
33. Michaeli, J., Rifkind, R. A. and Marks, P. A. (1992b) Differentiating agents in cancer therapy. In: Cancer Chemotherapy and Biological Response Modifiers: Annual 13, pp. 288-307, Piendo, H. M. P., Longo, D. and Chabner, B. A. (eds.) Elsevier, New York.
34. Pagano, M., Tam, S. W., Theodoras, A. M., Beer-Romero, P., Del Sal, G., Chau, V., Yew, P. R., Draetta, G. F. and Rolfe, M. (1995) Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685.
35. 1 events and regulation of cell proliferation. Science 246: 603-608.
36. Pierce, G. B. and Wallace, C. (1971) Differentiation of malignant to benign cells. Cancer Res. 31: 127-134.
37. Pines, J. and Hunter, T. (1990) Human cyclin A is adenovirus E1A-associated protein p60 and behaves differently from cyclin B. Nature (London) 346: 760-763.
38. Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-β and contact inhibition to cell cycle arrest. Genes & Dev. 8: 9-22.
39. Ramsay, R. G., Ikeda, K., Rifkind, R. A. and Marks, P. A. (1986) Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes and cell division. Proc. Natl. Acad. Sci. USA. 83: 6849-6853.
40. Reuben, R. C., Wife, R. L., Breslow, R., Rifkind, R. A. and Marks, P. A. (1976) A new group of potent inducers of differentiation in murine erythroleukemia cells. Proc. Natl. Acad. Sci. USA 73: 862-866.
41. Richon, V., Ramsay, R. G., Rifkind, R. A. and Marks, P. A. (1989) Modulation of the c-myb, c-myc and p53 mRNA and protein levels during induced murine erythroleukemia cell differentiation. Oncogene 4: 165-173.
42. Richon, V. M., Rifkind, R. A. and Marks, P. A. (1992) Expression and phosphorylation of the retinoblastoma protein during induced differentiation of murine erythroleukemia cells. Cell Growth Differ. 3: 413-420.
43. Richon, V. M. and Venta-Perez, G. (1996) Changes in E2F DNA-binding activity during induced erythroid differentiation. Cell Growth Differ. 7: 31-42.
44. Rowinsky, E. W., Ettinger, D. S., Grochow, L. B., Brudrett, R. B., Cates, A. E. and Donehower, R. C. (1986) Phase I and pharmacological study of hexamethylene bisacetamide (HMBA) in patients with advanced cancer. J. Clin. Oncol. 4: 1835-1844.
45. Rowinsky, E. W., Ettinger, D. S., McGuire, W. P., Noe, D. A., Grochow, L. B. and Donehower, R. C. (1987) Prolonged infusion of hexamethylene bisacetamide: a phase I and pharmacological study. Cancer Res. 47: 5788-5795.
46. Sachs, L. (1987) Cell differentiation and bypassing of genetic defects in the suppression of malignancy. Cancer Res. 47: 1981-1986.
47. Sardet, C., Vidal, M., Cobrinik, D., Geng, Y., Onufryk, C, Chen, A. and Weinberg, R. A. (1995) E2F-4 and E2F-5, two members of the E2F family, are expressed in early phases of the cell cycle. Proc. Natl. Acad. Sci. USA 92: 2403-2407.
48. Sherr, C. J. (1993) Mammalian G1 cyclins. Cell 73: 1059-1065.
49. Shin, E. K., Shin, A., Paulding, C., Schaffhausen, B. and Yee, A. (1995) Multiple changes in E2F function and regulation occur upon muscle differentiation. Mol. Cell. Biol. 15: 2252-2262.
50. Skapek, S. X., Rhee, J., Spicer, D. B. and Lassar, A. B. (1995) Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. Science 267; 1022-1024.
51. Terada, M., Nudel, U., Fibach, E., Rifkind, R. A. and Marks, P. A. (1978) Changes in DNA associated with induction of erythroid differentiation by dimethyl sulfoxide in murine erythroleukemia cells. Cancer Res. 38: 835-840.
52. Tsiftsoglou, A. S. and Wong, W. (1985) Molecular and cellular mechanisms of leukemia hemopoietic cell differentiation: an analysis of the Friend system. Anticancer Res. 5: 81-100.
53. Vairo, C., Livingston, D. M. and Ginsberg, D. (1995) Functional interaction between E2F-4 and p130: evidence for distinct mechanisms underlying growth suppression by different retinoblastoma protein family members. Genes & Dev. 9: 869-881.
54. Weinberg, R. (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323-330.
55. Won, K.-A., Xiong, Y., Beach, D. and Gilman, M. S. (1992) Growth-regulated expression of D-type cyclin genes in human diploid fibroblasts. Proc. Natl. Acad. Sci. USA 89: 9910-9914.
56. Wu, C.-L., Zukerberg, L. R., Ngwu, C., Harlow, E. and Lees, J. A. (1995) In vivo association of E2F and DP family proteins. Mol. Cell. Biol. 15: 2536-2546.
57. Young, C. W., Fanucchi, M. P., Walsh, T. B., Blatzer, L., Yaldaei, S., Stevens, Y. W., Gordon, C., Tong, W., Rifkind, R. A. and Marks, P. A. (1988) Phase I trial and clinical pharmacological evaluation of hexamethylene bisacetamide administration by ten-day continuous intravenous infusion at twenty-eight day intervals. Cancer Res. 48: 7304-7309.
58. Zhang, H., Hannon, G. J. and Beach, D. (1994) p21-containing cyclin kinases exist in both active and inactive states. Genes & Dev. 8: 1750-1758.
59. Zhuo, S., Fan, S., Huang, S. and Kaufman, S. (1995) Study of the role of retinoblastoma protein in terminal differentiation of murine erythroleukemia cells. Proc. Natl. Acad. Sci. USA 92: 4234-4238.